Dr. Reddy's Laboratories RDY announced today that it has launched Montelukast Sodium Oral Granules, a bioequivalent generic version of Singulair® (montelukast sodium) oral granules in the US market on September, 26, 2012, following the approval by the United States Food & Drug Administration (USFDA) of Dr.Reddy's ANDA for Montelukast Sodium Oral Granules.
The Singulair® Oral Granules brand had U.S. sales of approximately $61 million for the most recent twelve months ending July 2012 according to IMS Health*.
Dr. Reddy's Montelukast Sodium Oral Granules in 4 mg are available in unit dosage package of 30.
Disclaimer
This press release includes forward-looking
statements, as defined in the U.S. Private Securities Litigation Reform
Act of 1995. We have based these forward-looking statements on our
current expectations and projections about future events. Such
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results to differ materially. Such factors
include, but are not limited to, changes in local and global economic
conditions, our ability to successfully implement our strategy, the
market acceptance of and demand for our products, our growth and
expansion, technological change and our exposure to market risks. By
their nature, these expectations and projections are only estimates and
could be materially different from actual results in the future.
About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. RDY
is an integrated global pharmaceutical company, committed to providing
affordable and innovative medicines for healthier lives. Through its
three businesses - Pharmaceutical Services and Active Ingredients,
Global Generics and Proprietary Products – Dr. Reddy's
offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars, differentiated
formulations and NCEs. Therapeutic focus is on gastro-intestinal,
cardiovascular, diabetology, oncology, pain management, anti-infective
and pediatrics. Major markets include India, USA, Russia and CIS,
Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more
information, log on to: www.drreddys.com
Singulair® is a registered trademark of Merck Co.
*IMS National Sales Perspectives: Retail and Non-Retail MAT July 2012
Media:
S Rajan, +91-40-49002445
at
rajans@drreddys.com
or
Investors
and Financial Analysts:
Kedar Upadhye, +91-40-66834297
kedaru@drreddys.com
or
Saunak
Savla, +91-40-49002135
saunaks@drreddys.com
or
Milan
Kalawadia (USA), +1 908-203-4931
mkalawadia@drreddys.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.